Journal
ACTA PHARMACOLOGICA SINICA
Volume 43, Issue 1, Pages 194-208Publisher
NATURE PUBL GROUP
DOI: 10.1038/s41401-021-00752-y
Keywords
glioblastoma; benzimidazoles; cell cycle arrest; apoptosis; pyroptosis; drug repurposing
Funding
- Beijing Natural Science Foundation [7212157]
- CAMS Innovation Fund for Medical Sciences [2016-I2M-3-007]
- National Natural Science Foundation of China [81803584, 81703536]
- Technology Major Projects for Major New Drugs Innovation and Development [2018ZX09711001-005-025, 2018ZX09711001-012]
Ask authors/readers for more resources
Analysis of hub genes in GBM revealed benzimidazoles as potential anti-GBM agents, with in vivo studies showing their efficacy in suppressing tumor growth.
Glioblastoma multiforme (GBM) is the most malignant and lethal primary brain tumor in adults accounting for about 50% of all gliomas. The only treatment available for GBM is the drug temozolomide, which unfortunately has frequent drug resistance issue. By analyzing the hub genes of GBM via weighted gene co-expression network analysis (WGCNA) of the cancer genome atlas (TCGA) dataset, and using the connectivity map (CMAP) platform for drug repurposing, we found that multiple azole compounds had potential anti-GBM activity. When their anti-GBM activity was examined, however, only three benzimidazole compounds, i.e. flubendazole, mebendazole and fenbendazole, potently and dose-dependently inhibited proliferation of U87 and U251 cells with IC50 values below 0.26 mu M. Benzimidazoles (0.125-0.5 mu M) dose-dependently suppressed DNA synthesis, cell migration and invasion, and regulated the expression of key epithelial-mesenchymal transition (EMT) markers in U87 and U251 cells. Benzimidazoles treatment also dose-dependently induced the GBM cell cycle arrest at the G(2)/M phase via the P53/P21/cyclin B1 pathway. Furthermore, the drugs triggered pyroptosis of GBM cells through the NF-kappa B/NLRP3/GSDMD pathway, and might also concurrently induced mitochondria-dependent apoptosis. In a nude mouse U87 cell xenograft model, administration of flubendazole (12.5, 25, and 50 mg center dot kg(-1) center dot d(-1), i.p, for 3 weeks) dose-dependently suppressed the tumor growth without obvious adverse effects. Taken together, our results demonstrated that benzimidazoles might be promising candidates for the treatment of GBM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available